Back to search results

A Study of JNJ-87704916 for Advanced Solid Tumors

This study is looking at a new treatment called JNJ-87704916, given as an injection directly into the tumor. It will be tested alone and in combination with another drug called cetrelimab. The main goal is to find out how safe these treatments are and what doses work best. You might be able to join if you have an advanced solid tumor that has not responded to other treatments, or if you have metastatic (spread) or locally advanced non-small cell lung cancer (NSCLC). You also need to have at least one tumor that can be injected. The study will look at side effects and how many people experience them over a period of up to 5 years.

Study design
This is an interventional study with a planned enrollment of 126 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events from the first dose up to 100 days after the last dose of study treatment, and for dose-limiting toxicity for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06311578

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Johnson & Johnson Enterprise Innovation Inc.
~126 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:JNJ-87704916CetrelimabStandard of Care PD(L)-1

At a glance

Recruiting sites
9 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
Measured over Up to 5 years
+1 more outcome measured

Conditions

Neoplasms

Explore related trials

Lung Non-Small Cell CarcinomaSolid Neoplasm

Where it's being run

10 sites across 7 states
Spain3
Pennsylvania2
New York1
Texas1
Ontario1
Quebec1
France1

Study leadership

  • Johnson & Johnson Enterprise Innovation Inc Clinical Trial · STUDY_DIRECTOR · Johnson & Johnson Enterprise Innovation Inc.

Who to contact

Study Contact
[email protected]
844-434-4210
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; Part 2: Individuals with histologically or cytologically confirmed metastatic or locally advanced NSCLC
Have at least 1 injectable tumor
Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1
A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study
Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy

Exclusion

Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed
Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy
Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents
History of solid organ or hematologic stem cell transplantation
Known positive test result for human immunodeficiency virus (HIV) or other immunodeficiency syndrome
History of allergy to protein-based therapies or history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia)

What this trial measures

  • Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)Up to 5 years

    The DLTs are specific adverse events with defined non-hematological toxicities or hematologic toxicities as per the study protocol.

  • Number of Participants with Adverse Events (AEs) by SeverityFrom first dose up to 100 days after last dose of study treatment (up to 5 years)

    An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the treatment. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening, and Grade 5: death related to adverse event.